| Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled … K Park, EH Tan, K O'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ... The Lancet Oncology 17 (5), 577-589, 2016 | 1247 | 2016 |
| Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study MD Hellmann, NA Rizvi, JW Goldman, SN Gettinger, H Borghaei, ... The lancet oncology 18 (1), 31-41, 2017 | 1000 | 2017 |
| American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer DG Pfister, SA Laurie, GS Weinstein, WM Mendenhall, DJ Adelstein, ... Journal of clinical Oncology 24 (22), 3693-3704, 2006 | 636 | 2006 |
| Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial L Paz-Ares, EH Tan, K O’Byrne, L Zhang, V Hirsh, M Boyer, JCH Yang, ... Annals of Oncology 28 (2), 270-277, 2017 | 560 | 2017 |
| Nivolumab monotherapy for first-line treatment of advanced non–small-cell lung cancer S Gettinger, NA Rizvi, LQ Chow, H Borghaei, J Brahmer, N Ready, ... Journal of Clinical Oncology 34 (25), 2980, 2016 | 529 | 2016 |
| Nivolumab in combination with platinum‐based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer NA Rizvi, MD Hellmann, JR Brahmer, RA Juergens, H Borghaei, ... Journal of Clinical Oncology 34 (25), 2969, 2016 | 480 | 2016 |
| Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review SA Laurie, AL Ho, MG Fury, E Sherman, DG Pfister The lancet oncology 12 (8), 815-824, 2011 | 414 | 2011 |
| Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update AA Forastiere, N Ismaila, JS Lewin, CA Nathan, DJ Adelstein, A Eisbruch, ... Journal of Clinical Oncology 36 (11), 1143-1169, 2018 | 335 | 2018 |
| Systemic therapy in the palliative management of advanced salivary gland cancers SA Laurie, L Licitra Journal of clinical oncology 24 (17), 2673-2678, 2006 | 321 | 2006 |
| Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non–adenoid cystic carcinoma … M Agulnik, EWE Cohen, RB Cohen, EX Chen, EE Vokes, SJ Hotte, ... Journal of Clinical Oncology 25 (25), 3978-3984, 2007 | 286 | 2007 |
| Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non–small-cell lung cancer: NCIC Clinical Trials Group BR24 … GD Goss, A Arnold, FA Shepherd, M Dediu, TE Ciuleanu, D Fenton, ... Journal of clinical oncology 28 (1), 49-55, 2010 | 256 | 2010 |
| ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK … BC Cho, DW Kim, A Bearz, SA Laurie, M McKeage, G Borra, K Park, ... Journal of Thoracic Oncology 12 (9), 1357-1367, 2017 | 190 | 2017 |
| Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC S Gettinger, MD Hellmann, LQM Chow, H Borghaei, S Antonia, ... Journal of Thoracic Oncology 13 (9), 1363-1372, 2018 | 180 | 2018 |
| Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non–small-cell lung cancer SJ Crabb, D Patsios, E Sauerbrei, PM Ellis, A Arnold, G Goss, NB Leighl, ... Journal of Clinical Oncology 27 (3), 404-410, 2009 | 167 | 2009 |
| A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization SA Laurie, JC Bell, HL Atkins, J Roach, MK Bamat, JD O'Neil, MS Roberts, ... Clinical Cancer Research 12 (8), 2555-2562, 2006 | 165 | 2006 |
| Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non–small-cell lung cancer and poor performance status G Goss, D Ferry, R Wierzbicki, SA Laurie, J Thompson, B Biesma, ... Journal of Clinical Oncology 27 (13), 2253, 2009 | 155 | 2009 |
| Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC): metastatic non-small … SJ Antonia, JR Brahmer, S Gettinger, LQ Chow, R Juergens, ... International Journal of Radiation Oncology, Biology, Physics 90 (5), S2, 2014 | 153 | 2014 |
| Phase I study of green tea extract in patients with advanced lung cancer SA Laurie, VA Miller, SC Grant, MG Kris, KK Ng Cancer chemotherapy and pharmacology 55, 33-38, 2005 | 137 | 2005 |
| Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. RM Lorence, AL Pecora, PP Major, SJ Hotte, SA Laurie, MS Roberts, ... Current opinion in molecular therapeutics 5 (6), 618-624, 2003 | 134 | 2003 |
| Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in … SA Laurie, I Gauthier, A Arnold, FA Shepherd, PM Ellis, E Chen, G Goss, ... Journal of clinical oncology 26 (11), 1871-1878, 2008 | 128 | 2008 |
